Front Row Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Front Row Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2	Buy	+1	New	+$3	﹤0.01%	574
2026 Q1	–	Sell	-1	Closed	-$4	–	576
2025 Q4	$4	Hold	1	–	–	﹤0.01%	552
2025 Q3	$39	Hold	1	–	–	﹤0.01%	545
2025 Q2	$23	Sell	1 -1	-50%	-$24	﹤0.01%	531
2025 Q1	$30	Hold	2	–	–	﹤0.01%	505
2024 Q4	$37	Hold	2	–	–	﹤0.01%	496
2024 Q3	$25	Hold	2	–	–	﹤0.01%	498
2024 Q2	$21	Hold	2	–	–	﹤0.01%	936
2024 Q1	$73	Hold	2	–	–	﹤0.01%	919
2023 Q4	$59	Hold	2	–	–	﹤0.01%	467
2023 Q3	$134	Hold	2	–	–	﹤0.01%	905
2023 Q2	$0	Hold	2	–	–	﹤0.01%	962
2023 Q1	$0	Buy	+2	New	+$670	﹤0.01%	964

Other funds holding TVRD

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AFG

American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Front Row Advisors's TVRD Position: Q2 2026 in Review

Front Row Advisors opened a new position in Tvardi Therapeutics (TVRD) in Q2 2026: 1 share worth $2. The stake represents ﹤0.01% of the portfolio and ranks #574 among its holdings. This is a return to the name: Front Row Advisors previously reported a position in TVRD as recently as Q4 2025.

Front Row Advisors first reported a position in TVRD in Q1 2023 and has held it in 13 quarters since. The position peaked at $134 in Q3 2023. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

Front Row Advisors held 1 share of Tvardi Therapeutics worth $2 as of Q2 2026.
Tvardi Therapeutics was a new Front Row Advisors position in Q2 2026.
Tvardi Therapeutics made up ﹤0.01% of Front Row Advisors's portfolio in Q2 2026, its #574 holding.
Front Row Advisors first reported a position in Tvardi Therapeutics in Q1 2023 and has held it in 13 quarters since.
Front Row Advisors's Tvardi Therapeutics position peaked at $134 in Q3 2023.
58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.